Last $0.49 USD
Change Today +0.08 / 19.51%
Volume 86.7K
INNV On Other Exchanges
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

innovus pharmaceuticals inc (INNV) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/23/13 - $1.16
52 Week Low
07/8/14 - $0.11
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

innovus pharmaceuticals inc (INNV) Related Businessweek News

No Related Businessweek News Found

innovus pharmaceuticals inc (INNV) Details

Innovus Pharmaceuticals, Inc., a pharmaceutical company, is engaged in the commercialization, licensing, and development of non-prescription pharmaceutical and consumer health products in the United States and internationally. Its male and female sexual health and vitality products include EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; CIRCUMserum, a non-medicated cream to alleviate reduced penile sensitivity; Zestra, a non-medicated patented natural product to increase desire and arousal, and reduce pain from sexual intercourse in women; and Zestra Glide, a clinically tested water-based longer lasting lubricant. The company also provides pain management products comprising Apeaz, an OTC monograph-compliant topical cream for the relief of arthritis pain; and Xyralid, an OTC monograph compliant lidocaine-based spray in development for the relief of hemorrhoids. It markets its products directly or through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through on-line channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. is based in San Diego, California.

2 Employees
Last Reported Date: 03/28/14

innovus pharmaceuticals inc (INNV) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: --
Compensation as of Fiscal Year 2013.

innovus pharmaceuticals inc (INNV) Key Developments

Innovus Pharmaceuticals, Inc. Signs Exclusive Marketing Sales and Distribution Agreement with Tramorgan Limited to Market and Distribute Sensum+(TM) in the United Kingdom

Innovus Pharmaceuticals, Inc. announced that it has entered into an exclusive marketing and distribution agreement with Tramorgan Limited under which Innovus Pharma has granted to Tramorgan an exclusive marketing sales and distribution right to market and sell Innovus Pharma's topical consumer care product to increase penile sensitivity, Sensum+(tm) in the United Kingdom ('UK'). The agreement has an initial term of December 31, 2016 and can be extended thereafter for a twenty-four month period if Tramorgan has reached certain aggregate sales milestones. Pursuant to the agreement, Innovus Pharma is eligible to receive (a) up to $44 million dollars in sales milestone payments based on Tramorgan's attainment of certain levels of cumulative gross sales amounts plus (b) 50% royalties based on Tramorgan's net sales after distribution costs in the UK. The product will be available in 10ml multi-dose dispenser and single use packets. This is its second international partnership for Sensum+(tm) and its first one in Europe for this product. Tramorgan is a leader in government health sales and has extensive connections into the UK market both on the retail side and online.

Innovus Pharma Expands US Distribution by Signing Non-Exclusive Sampling and Distribution Agreement With Bulu Box(R) for Zestra(R) in the US

Innovus Pharmaceuticals, Inc. announced it has entered into an non-exclusive sampling, marketing and distribution agreement with Bulu Box(R) under which Bulu Box will add Zestra(R) as part of its monthly box to all current subscribers. In addition, Bulu Box will sell Zestra(R) 3 packettes box through its E-commerce platform in the US.

Innovus Pharmaceuticals, Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-12-2014 08:00 AM

Innovus Pharmaceuticals, Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-12-2014 08:00 AM. Venue: The Encore at Wynn Las Vegas, 3121 Las Vegas Blvd. South, Las Vegas, NV 89109, United States. Speakers: Bassam B. Damaj, Chief Executive Officer, President and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INNV:US $0.49 USD +0.08

INNV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for INNV.
View Industry Companies

Industry Analysis


Industry Average

Valuation INNV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 40.8x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 38.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INNOVUS PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at